Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial.
about
The gut hormones in appetite regulationThe metabolic vascular syndrome - guide to an individualized treatmentThe L-Cell in Nutritional Sensing and the Regulation of AppetiteObesity pharmacotherapy: current perspectives and future directionsAddressing unmet medical needs in type 2 diabetes: a narrative review of drugs under developmentUnraveling oxyntomodulin, GLP1's enigmatic brotherTherapy for obesity based on gastrointestinal hormonesAction and therapeutic potential of oxyntomodulinMicrobial regulation of GLP-1 and L-cell biologyUpdate on the treatment of type 2 diabetes mellitusGut hormones and the regulation of energy homeostasisThe relationship between gut and adipose hormones, and reproductionThe future role of gut hormones in the treatment of obesityRobust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primatesCentral and peripheral molecular targets for antiobesity pharmacotherapy.The pharmacological treatment and management of obesity.Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.Regulation of appetite to treat obesity.New advances in models and strategies for developing anti-obesity drugs.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Food preferences and underlying mechanisms after bariatric surgery.Brain imaging studies of appetite in the context of obesity and the menstrual cycle.Obesity treatment: novel peripheral targets.Obesity pharmacotherapy: what is next?The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes.Sizing up pharmacotherapy for obesityEvaluations of Actiheart, IDEEA® and RT3 monitors for estimating activity energy expenditure in free-living womenPeripheral mechanisms in appetite regulation.The role of gut hormones in glucose homeostasisGastrointestinal regulation of food intake.The gut sensor as regulator of body weight.Gut-Brain Endocrine Axes in Weight Regulation and Obesity PharmacotherapyBariatric surgery for extreme adolescent obesity: indications, outcomes, and physiologic effects on the gut-brain axisRole of gastrointestinal hormones in feeding behavior and obesity treatment.Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats.Gut hormones: the future of obesity treatment?Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemiaProglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in RatsSystemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release.Central control of body weight and appetite.
P2860
Q21296779-84E11B4A-AAEC-4D1F-B0D6-815BDE8BC33CQ26767142-F17B692C-EBB3-4720-8024-790C01CD916BQ26799942-A463056A-DB81-4D9F-80C6-8BA9FB22D069Q26828559-C4A4C610-A7AB-49A3-B0D1-1E8FBC93C79BQ26830274-AECE251B-AA9E-4717-B5D9-5526154408F5Q27001704-27486025-7B69-49C4-A547-214618F876ECQ27006777-505F77E1-BFEF-42FB-B293-0E5FED362D9CQ27025870-161BC43C-B2A6-4E37-887E-EA82785B9D56Q28072517-29E15B45-C4AC-4E34-B3B1-BAB2CEF5E4C1Q28073342-35805D2E-4F32-4164-B11F-751140A6D16FQ28278826-5258F7AD-E66A-425D-BCF9-0EE6333120B6Q28301116-FD4BA4EF-9FE9-4607-BBD0-C407CDD5AFDFQ30357431-9262CC39-8946-4900-8066-03661B7B0ADBQ30368984-7A1C3EFF-7DC0-4DF4-9537-15BF4B8B3633Q30388865-0667063D-9951-4379-8361-64F09320DC2FQ30399340-8F74F324-26AC-4ADB-9945-C4088ED271ABQ30399390-287C4AA8-9C8F-45A4-9160-C2E8C518F996Q30403705-896F3912-AD57-4F44-A04A-35ECC179BD63Q30429816-C46FE8D4-FC20-4B06-A29B-E20A0FCFAF78Q30597265-A73FCF72-35D2-44C7-A519-D42EDE49BDEBQ30954475-E3E9DF38-B1E0-4FC4-9677-5D53F35D8D69Q33516301-3D4C8377-A7FF-4DE7-A901-B51197F33D59Q33607971-A8946439-49B1-4946-A58A-7D95B18C9B28Q33827988-9A0A085D-F3F2-4CF2-AFCA-22A9E208976DQ33941355-92E599B4-7072-4FE1-98D4-4AC34183B6D5Q33969368-B4B375FA-6D9C-4834-A6B8-16B809E39486Q34127172-F645314A-0EC6-4761-8495-8E001C4685ABQ35204654-FCF8AF23-CA2D-4ED3-9AE7-61DFDB495E13Q35251016-81891B41-FEFF-48F1-865C-4E46CD30EDBBQ35251043-730D1F38-B95A-4C45-A936-8E7D485F637BQ35535513-AADE1A51-7A59-46E3-873E-ADD4EEAB8D68Q35667150-C4F2EC37-A8F4-4435-A890-416812364682Q35677192-C4F59B05-D7AA-41DD-98B2-8256649D654BQ35766237-C80DE0F9-D540-450A-B04D-288531962C99Q36431249-591BF5AE-C50F-48FF-874F-96CD15A22538Q36468102-1586B773-59F7-43CA-BBDD-0363F074F5C3Q36720596-31248CB6-D97E-4B19-A838-F9814E9D3F22Q36763274-DA10D1FD-87E3-41B0-B477-C11914838E93Q36929467-F39FB435-812D-47F5-B35D-24D664DF9281Q36979763-E0243DF9-4512-4802-941C-5CFEC75E503A
P2860
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Oxyntomodulin increases energy ...... a randomised controlled trial.
@ast
Oxyntomodulin increases energy ...... a randomised controlled trial.
@en
Oxyntomodulin increases energy ...... a randomised controlled trial.
@nl
type
label
Oxyntomodulin increases energy ...... a randomised controlled trial.
@ast
Oxyntomodulin increases energy ...... a randomised controlled trial.
@en
Oxyntomodulin increases energy ...... a randomised controlled trial.
@nl
prefLabel
Oxyntomodulin increases energy ...... a randomised controlled trial.
@ast
Oxyntomodulin increases energy ...... a randomised controlled trial.
@en
Oxyntomodulin increases energy ...... a randomised controlled trial.
@nl
P2093
P2860
P356
P1476
Oxyntomodulin increases energy ...... a randomised controlled trial.
@en
P2093
M A Ghatei
P2860
P2888
P304
P356
10.1038/SJ.IJO.0803344
P407
P577
2006-04-18T00:00:00Z
P5875
P6179
1047343368